BACKGROUND: Human immunodeficiency virus (HIV)-infected children are at increased risk of meningococcal infection and poor response to quadrivalent meningococcal conjugate vaccine (MCV4), but MCV4 has not been studied in preadolescent HIV-infected children. METHODS: The P1065 trial enrolled 2- to 10-year-old HIV-infected children with CD4 ≥ 25% to receive MCV4 at entry and at week 24. Rates of response (≥ 4-fold increase in rabbit serum bactericidal antibody) against each meningococcal serogroup (A, C, Y, W-135), geometric mean titers, and rates of seroprotection (rabbit serum bactericidal antibody titer ≥ 1:128) were determined from sera obtained at entry and weeks 4, 24, 28, and 72. Adverse events were assessed for 6 weeks after each MCV4 dose. RESULTS: At entry, 47% of the 59 participants were male, 56% black, 31% Latino, median age was 6 years, 88% were receiving antiretroviral therapy, and 75% had viral load <400 copies/mL. There were no serious adverse events within 6 weeks after MCV4 doses; all vaccination reactions were mild. Response after a single MCV4 dose was high to serogroup A (92%) and W-135 (98%); responses improved after a second dose for serogroup C (43%-80%) (P < 0.0001) and Y (76%-84%) (P = 0.38). By week 72, seroprotection rates were 93%, 91%, 78%, and 46% for serogroups W-135, Y, A, and C, respectively. CONCLUSIONS: Two doses of MCV4 were safe and immunogenic in 2- to 10-year-old HIV-infected children. The second dose increased the proportion of children who made a response to serogroup C. Seroprotection waned substantially for serogroups A and C within 1 year of last MCV4 dose.
BACKGROUND: Human immunodeficiency virus (HIV)-infectedchildren are at increased risk of meningococcal infection and poor response to quadrivalent meningococcal conjugate vaccine (MCV4), but MCV4 has not been studied in preadolescent HIV-infectedchildren. METHODS: The P1065 trial enrolled 2- to 10-year-old HIV-infectedchildren with CD4 ≥ 25% to receive MCV4 at entry and at week 24. Rates of response (≥ 4-fold increase in rabbit serum bactericidal antibody) against each meningococcal serogroup (A, C, Y, W-135), geometric mean titers, and rates of seroprotection (rabbit serum bactericidal antibody titer ≥ 1:128) were determined from sera obtained at entry and weeks 4, 24, 28, and 72. Adverse events were assessed for 6 weeks after each MCV4 dose. RESULTS: At entry, 47% of the 59 participants were male, 56% black, 31% Latino, median age was 6 years, 88% were receiving antiretroviral therapy, and 75% had viral load <400 copies/mL. There were no serious adverse events within 6 weeks after MCV4 doses; all vaccination reactions were mild. Response after a single MCV4 dose was high to serogroup A (92%) and W-135 (98%); responses improved after a second dose for serogroup C (43%-80%) (P < 0.0001) and Y (76%-84%) (P = 0.38). By week 72, seroprotection rates were 93%, 91%, 78%, and 46% for serogroups W-135, Y, A, and C, respectively. CONCLUSIONS: Two doses of MCV4 were safe and immunogenic in 2- to 10-year-old HIV-infectedchildren. The second dose increased the proportion of children who made a response to serogroup C. Seroprotection waned substantially for serogroups A and C within 1 year of last MCV4 dose.
Authors: Michael Pichichero; Janet Casey; Mark Blatter; Edward Rothstein; Robert Ryall; Mike Bybel; Gregory Gilmet; Thomas Papa Journal: Pediatr Infect Dis J Date: 2005-01 Impact factor: 2.129
Authors: Harry Keyserling; Thomas Papa; Katalin Koranyi; Robert Ryall; Ehab Bassily; Michael J Bybel; Kevin Sullivan; Gregory Gilmet; Al Reinhardt Journal: Arch Pediatr Adolesc Med Date: 2005-10
Authors: P Richmond; E Kaczmarski; R Borrow; J Findlow; S Clark; R McCann; J Hill; M Barker; E Miller Journal: J Infect Dis Date: 2000-02 Impact factor: 5.226
Authors: Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Mark J Abzug; Stephen I Pelton; Lin-Ye Song; Terence Fenton; Myron J Levin; Sharon A Nachman; William Borkowsky; Howard M Rosenblatt; John F Marcinak; Arry Dieudonne; Elaine J Abrams; Indu Pathak Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Philimon Gona; Russell B Van Dyke; Paige L Williams; Wayne M Dankner; Miriam C Chernoff; Sharon A Nachman; George R Seage Journal: JAMA Date: 2006-07-19 Impact factor: 56.272
Authors: Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer Journal: Pediatr Infect Dis J Date: 2015-05 Impact factor: 2.129
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Meredith G Warshaw; George K Siberry; Paige Williams; Michael D Decker; Patrick Jean-Philippe; Jorge Lujan-Zilbermann Journal: J Pediatric Infect Dis Soc Date: 2017-09-01 Impact factor: 3.164
Authors: Ruth D Simmons; Peter Kirwan; Kazim Beebeejaun; Andrew Riordan; Ray Borrow; Mary E Ramsay; Valerie Delpech; Samuel Lattimore; Shamez Ladhani Journal: BMC Med Date: 2015-12-09 Impact factor: 8.775